EIB and Angelini Ventures’ Partnership Reaches €48.5 Million in Investments

Rome, 16 September 2026

• New €17 million investment into MMI, a microsurgery robotics company, marks the third investment completed under the €150 million partnership in less than 12 months, following ADCytherix and Nuclidium
• A further €20 million has been committed to two additional companies developing new approaches in oncology and rare diseases
• Partnership remains on track to invest in 7-10 European companies, with approximately €100 million expected to be invested or committed by early 2027
  
  

The European Investment Bank (EIB) and Angelini Ventures, the venture capital firm of Angelini Industries, today announced a €17 million co-investment in MMI, which develops robotic solutions for microsurgery and super-microsurgery, including the Pisa-manufactured Symani system, equipped with the world's smallest articulated robotic instruments.

The transaction marks the third investment completed under the partners’ €150 million initiative in less than 12 months, highlighting the rapid deployment of capital to breakthrough European life sciences companies.

A further €20 million has been committed to two European life sciences companies focused respectively on oncology and rare diseases, with details to be announced following completion of the respective financings. This brings the amount already co-invested by the partnership to €48.5 million, rising to €68.5 million when the two committed investments are included.

With five investments either completed or committed, the EIB and Angelini Ventures are making strong progress towards their goal of backing 7 to 10 European companies under the €150 million facility, with approximately €100 million expected to be invested or committed by early 2027.

“In less than a year, our partnership with the EIB has already resulted in investments in five European life sciences companies,” said Paolo Di Giorgio, CEO of Angelini Ventures. “What stands out is the breadth of innovation behind these companies, from breakthrough medical technologies to new therapeutic approaches. Our focus is on science and technology that can fundamentally change how diseases are treated or care is delivered, and on identifying the companies best positioned to turn that potential into successful businesses. The quality of the opportunities we continue to see makes us very excited about what this partnership can deliver next.”

“Europe’s future competitiveness depends on its ability to turn scientific excellence into global success stories,” said EIB Vice-President Gelsomina Vigliotti. “Through our partnership with Angelini Ventures, we are combining capital, expertise and long-term vision to support Europe’s most promising healthcare innovators. By helping breakthrough technologies scale and reach patients faster, we are strengthening Europe’s innovation ecosystem while delivering tangible benefits for society.”

The EIB-Angelini Ventures agreement

The EIB and Angelini Ventures signed their €150 million co-investment partnership in December 2025, with each committing €75 million over six years to support 7–10 European companies developing innovative solutions across biotechnology, medtech and digital health.

The partnership is the first agreement of its kind between the EIB and a corporate venture capital investor in the healthcare sector.

The first companies backed through the initiative were ADCytherix, a French biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer, and Nuclidium, a clinical-stage radiopharmaceutical company developing copper-based radiotheranostics for the diagnosis and treatment of cancer. The EIB and Angelini Ventures co-led an extension of Nuclidium’s Series B financing. MMI, a medical technology company developing robotic systems for microsurgery, is the third investment completed under the partnership.

The initiative is aligned with TechEU, the EIB Group programme designed to support European innovation and technological leadership. Through TechEU, the EIB Group aims to invest €70 billion in equity, quasi-equity, loans and guarantees between 2025 and 2027, with the ambition of mobilising €250 billion in investment in the real economy.

ENDS

Background information

EIB Group   
The European Investment Bank (EIB) Group is the financing arm of the European Union, owned by the 27 Member States, and one of the largest multilateral development banks in the world. In 2025, the EIB Group signed €100 billion in new financing and advisory services for over 870 high-impact projects under eight core priorities that support EU policy objectives: climate action and the environment, digitalisation and technological innovation, security and defence, territorial cohesion, agriculture and the bioeconomy, social infrastructure, strong global partnerships and the savings and investments union. Beyond long-term loans for large infrastructure, the EIB Group crowds in private investment for high-risk innovative projects and businesses, with a growing role in Europe’s markets for venture debt, venture capital, guarantees and securitisations. 

The European Investment Fund (EIF) is the subsidiary of the EIB Group specialised in providing guarantees, securitisation and equity to improve access to finance for small and medium-sized businesses and startups across Europe. Acting as an anchor investor, through its extensive network of partnering banks and investment funds, the EIF mobilises private investment and nurtures the ecosystem of venture capital funds to support innovative European entrepreneurs. 

Photos of the EIB Group's representatives and headquarters, logo files and video B-roll for media use are available here.  

Angelini Ventures is an international venture capital company and part of Angelini Industries, an Italian industrial group working in health, industrial technology and consumer goods. Angelini Ventures was formed in 2022 with planned investments of €300 million, about €150 million of which have already been allocated to startups developing innovative solutions and ideas in biotechnology, medtech and digital health. It invests in innovative companies in Europe and North America that can improve patients’ life expectancy and quality of life. The company is based in Rome and has a global team of 25 professionals working in nine cities (Rome, Milan, Turin, London, Singapore, Boston, Berlin, Dubai, Geneva, New York, Munich, Basel and Paris). Angelini Ventures is part of Angelini Industries’ strategy to promote innovation by combining existing capabilities and new skills to identify, finance and implement solutions that innovate on traditional healthcare models.

www.angeliniventures.com

Press contacts

EIB: Lorenzo Squintani, l.squintani@eib.org, tel.: +39 366 57 90 312
Website: www.eib.org/press

Angelini Ventures
Martina Palmese, Communications Coordinator – martina.palmese@angeliniventures.com  

SEC Newgate Italia
Daniele Pinosa – daniele.pinosa@secnewgate.it – tel. +39 3357233872
Fausta Tagliarini – fausta.tagliarini@secnewgate.it – tel. +39 3476474513
Daniele Murgia – daniele.murgia@secnewgate.it – tel. +39 3384330031
Giulia Cominotti – giulia.cominotti@secnewgate.it – tel. +39 3391499949

MEDiSTRAVA - Outside Italy
Sylvie Berrebi, Sandi Greenwood, Mark Swallow
angeliniventures@medistrava.com

Paolo di Giorgio - CEO of Angelini Ventures